Biobehavioral Factors and Cancer Progression: Physiological Pathways and Mechanisms

Susan K. Lutgendorf, PhD and Anil K. Sood, MD

Epidemiologic evidence increasingly has supported the role of biobehavioral risk factors such as social adversity, depression, and stress in cancer progression. This review describes in vitro, in vivo, and clinical studies demonstrating relationships between such processes and pathways involved in cancer progression. These include effects on the cellular immune response, angiogenesis, invasion, anoikis, and inflammation. Biobehavioral factors have been shown to contribute to the cross talk between tumor and host cells in the tumor microenvironment, and stress effects on host cells such as macrophages seem to be critical for many pathways involved in tumor progression. Some effects are bidirectional in that tumor-derived inflammation seems to affect central nervous system processes, giving rise to vegetative symptoms and contributing to dysregulation of the hypothalamic-pituitary-adrenal axis with downstream effects on inflammatory control. Findings to date are reviewed, and fruitful areas for future research are discussed. **Key words:** biobehavioral, stress, cancer, social support, angiogenesis.

HPA = hypothalamic-pituitary-adrenal; **ECM** = extracellular matrix; **MMP** = matrix metalloproteinase; **CNS** = central nervous system; **NK** = natural killer; **TIL** = tumor-infiltrating lymphocyte; **VEGF** = vascular endothelial growth factor; **IL** = interleukin; **NE** = norepinephrine; **TAM** = tumor-associated macrophage; **FAK** = focal adhesion kinase.

INTRODUCTION

Ever since the time of the ancient Greeks, there has been an interest in the relationship between psychological states and cancer (1). Epidemiologic studies have highlighted several key psychological factors related to both cancer initiation (development of cancer in patients with no previous tumor) and progression (expansion of disease in patients with existing cancers). The most commonly studied factors have been chronic stress, depression/distress, and social support/isolation. Epidemiologic data supporting a potential role of psychological factors as related to cancer initiation have been relatively equivocal (2–4), with the most consistent evidence pointing to a relationship of cancer incidence with severe life events, severe distress, or long-term depression (5,6). A more consistent association has been observed between psychosocial risk factors such as depression (7–9), distress (10), trauma history (11), social isolation (12–14), and more rapid cancer progression. Recent meta-analyses have linked depression (15), stressful life events (10,16), and social isolation (17) with poorer survival in patients with cancer. Although not all findings are consistent

(18,19), the predominance of epidemiologic evidence supports a relationship between psychosocial factors and cancer progression. Thus, this review will focus on data related to cancer progression.

MODEL OF THE SOCIOENVIRONMENTAL MACROENVIRONMENT AND CANCER PROGRESSION

A conceptual model has been proposed linking socioenvironmental factors in the "macroenvironment" and cancer progression (20). According to this model, central nervous system (CNS) perceptions of threat from environmental stressors, such as negative life events, socioeconomic burden, relationship difficulties, social isolation, and so on, interact with an individual's characteristic attitudes, perceptions, and coping abilities, resulting in conditions such as perceived stress, distress, loneliness, and the like. These states, particularly when experienced chronically, lead to downstream activation of neuroendocrine pathways including the autonomic nervous system and the hypothalamic-pituitary-adrenal (HPA) axis. Catecholamines, glucocorticoids, and other stress hormones and neuropeptides (e.g., oxytocin, dopamine) are released via the brain, the sympathetic nervous system, and/or the HPA axis. Neuroendocrine stress hormones in the tumor microenvironment assert a systemic influence on tumor growth. Psychosocial factors such as active coping, resilience, optimism, and social support may act to buffer the elicitation of the stress response. It should be noted that, although psychology has elaborated definite distinctions between constructs such as "stress," "distress," "depression," and "social isolation" at this point in the development of biobehavioral oncology research, the biological signatures of these various constructs have not been well differentiated with respect to processes at the tumor level. The preclinical studies generally use stress-related paradigms. Thus, we have adopted the relatively imprecise approach of describing constructs such as depression and social isolation along with stress as "biobehavioral risk factors" to convey the general phenomenon that biobehavioral processes seem to systematically affect a variety of important hallmarks of cancer biology. Because most of the emerging work described later has involved the sympathetic nervous system and the HPA axis, discussion will focus on these two stress response systems;

BIOBEHAVIORAL FACTORS AND CANCER PROGRESSION

however, it is likely that a variety of other neuroendocrine hormones may also influence the biological processes described later.

Early research examining CNS effects on cancer predominantly focused on downregulation of the immune response as a potential mediator of impaired surveillance for metastatic spread (21–25). Other work focused on stress effects on DNA repair (26,27). Given the unlikely role of a singular system in explaining the biological effects of stress pathways on cancer progression, during the last 10 years, the focus of mechanistic biobehavioral oncology research has broadened to include examination of the effects of stress on a) tumor angiogenesis, b) invasion and anoikis, c) stromal cells in the tumor microenvironment, and d) inflammation.

BIOBEHAVIORAL FACTORS AND THE CELLULAR IMMUNE RESPONSE IN CANCER PROGRESSION

Substantial evidence has demonstrated that negative psychosocial states, such as chronic stress, depression, and social isolation, are associated with downregulation of the cellular immune response, mediated largely by adrenergic and glucocorticoid signaling (28–30). For example, among patients with breast cancer, after surgery, low levels of social support and distress have been linked with decrements in indicators of cellular immunity, including impaired natural killer (NK) cell cytotoxicity (31–33), blunted T-cell production of T helper 1 versus T helper 2 cytokines (34), and decreased T-cell proliferative response to mitogens (33). Depression has also been associated with a poorer cellular immune response to specific antigens in patients with breast cancer (35). It should be noted, however, that not all findings have been consistent in this literature (e.g., Von et al. (36)).

Tumors have well-developed escape mechanisms by which they interfere with immune cell signaling and thus evade recognition and destruction by the immune response (37,38). Thus, the immune response in the tumor microenvironment is substantially downregulated compared with that in peripheral blood. We therefore considered whether stress-related influences would operate within the tumor microenvironment. Among patients with ovarian cancer at the time of surgery, NK cell activity in tumor-infiltrating lymphocytes (TILs) was diminished by more than 50%, compared with NK cell activity in lymphocytes isolated from peripheral blood, reflecting substantial downregulation. Nevertheless, biobehavioral factors were related to the cellular immune response in TIL. Specifically, social support was related to greater NK cell activity in both peripheral blood and TIL, whereas distress was associated with blunted NK cell activity in TIL and poorer T-cell production of T helper 1 versus T helper 2 cytokines in peripheral blood, ascites, and TIL (39,40). These findings suggest that biobehavioral risk factors do have some association with immune activity in the tumor microenvironment and underscore the importance of examining associations between bio-

behavioral factors and immune cells directly in the tumor microenvironment.

One issue that bears further comment is the extent to which relationships with markers of the immune response are predictive of disease recurrence and survival. This question has been difficult to investigate because of the large sample size and the relatively extensive follow-up required. One study reported that depressed patients with hepatobiliary carcinoma had lower NK cell numbers and shorter survival compared with their nondepressed counterparts and that NK cell count mediated the relationship between depression and survival (7). However, in general, the extent to which stress-related changes in the immune response are relevant for recurrence and survival is still unclear, and biobehavioral survival studies among patients with breast cancer have not reported a mediating role for NK cell activity (23,41).

Preclinical experimental studies with animal models have demonstrated similar patterns. For example, stress-induced release of catecholamines and prostaglandins, particularly in the perisurgical period, have been shown to suppress key components of the cellular immune response, including NK cell activity, which may allow for more aggressive course of disease (42–47).

ANGIOGENESIS AND INVASION

Cancer-related mortality largely results from the spread of cancer cells from the primary tumor to other sites in the body, a process called *metastasis*. Successful metastatic spread requires several sequential steps, including angiogenesis, proliferation, invasion, embolization, and colonization of a new secondary site (48). Many of these steps involve complex signaling interactions with surrounding cells. Stress response pathways have now been shown to influence many parts of this cascade including activities of both stromal and tumor cells (Fig. 1).

Tumor growth and metastatic spread are dependent on the development of adequate vascularization, a process called *angiogenesis*. This process is tightly controlled by a variety of positive and negative factors secreted by both tumor and host cells in the tumor microenvironment (49,50). Angiogenesis-promoting factors include vascular endothelial growth factor (VEGF), interleukin (IL) 6, IL-8, tumor necrosis factor α, and a variety of other molecules (51,52). In vitro, in vivo, and clinical studies have demonstrated links between biobehavioral factors and angiogenic pathways. For example, among patients with ovarian cancer at the time of surgery, higher levels of social support were associated with lower levels of VEGF both in serum (53) and in tumor tissue (54). Similarly, among patients with colon cancer, loneliness was related to higher levels of tumor VEGF at the time of surgery (55), and depression and poor quality of life were associated with higher level of serum VEGF both before and 6 weeks after surgery (56). Each of these studies controlled for relevant clinical variables. In vitro experiments in ovarian, melanoma, myeloma, and nasopharyngeal cancer cell lines have demonstrated that norepinephrine (NE) and the β-agonist isoproterenol profoundly stimulated

Figure 1. Effects of stress and psychosocial processes on the tumor microenvironment. The stress response results in activation of the autonomic nervous system and the hypothalamic-pituitary-adrenal axis. Factors released from these pathways can have direct effects on the tumor microenvironment, resulting in a favorable environment for tumor growth and progression. These dynamics can also adversely affect patient's quality of life. CRH = corticotrophin-releasing hormone; ACTH = adrenocorticotrophic hormone; NK = natural killer; T-regs = regulatory T cells; TAM = tumor-associated macrophage; MMPs = matrix metalloproteinases; VEGF = vascular endothelial growth factor; IL = interleukin; STAT3 = signal transducer and activator of transcription factor 3; QOL = quality of life. Reprinted with permission from Lutgendorf et al. (J Clin Oncol 2010;28:4094–9). Copyright 2010, American Society of Clinical Oncology.

expression of VEGF, which was blocked by the β-blocker propranolol (57–61). Further support for these pathways has come from preclinical experiments with orthotopic mouse models of ovarian cancer. Both chronic restraint stress and surgical stress have been shown to increase ovarian tumor weight and invasiveness—changes that were mediated by NE-driven increases in VEGF and angiogenesis (61,62). These effects were completely blocked by propranolol, a nonspecific β-blocker, thus confirming the role of adrenergic signaling

underlying these effects. Social isolation has been shown to have similar effects on tumor weight and invasiveness (61).

IL-6 is another cytokine that plays a key role in tumor angiogenesis, attachment, and invasion. It is produced by tumor cells and tumor-associated macrophages (TAMs) (63,64). Elevated IL-6 levels were observed in both plasma and ascites (the malignant effusions surrounding tumors) in patients with advanced stage ovarian cancer with low levels of social support, thus paralleling the VEGF findings described previously (65). Stress hormones such as NE have been shown to induce production of IL-6 and IL-8 by ovarian cancer and melanoma cells (59,63), demonstrating effects of stress response pathways on tumor-signaling mechanisms. Consistent with these findings, we have observed elevated levels of tumor, but not plasma, NE among patients with low levels of social support, suggesting the possibility that these social support findings may be adrenergically mediated at the tumor level (66).

The ability of tumor cells to detach from the primary tumor, invade through the basement membrane, and enter the vascular system is another critical step in the metastatic cascade. Matrix metalloproteinases (MMPs) are enzymes secreted by both tumor and stromal cells that facilitate the breakdown and remodeling of the extracellular matrix (ECM), thus enabling both local and distal tumor spread (67). Stress hormones promote the migration and invasion of tumor cells in multiple ways, including stimulation of MMP production by both stromal and tumor cells. Levels of NE commensurate with those that would be observed during the stress response have been shown to increase the in vitro invasive potential of ovarian cancer cells by 89% to 198%, a process that was blocked by propranolol (68). This effect was mediated by increased MMP-2 and MMP-9 levels in response to NE (68). Similar biological effects have been reported in several other tumor types including colon and head and neck cancers (58,69–71).

Stress Effects on Anoikis

Cells other than hematopoietic cells are anchorage dependent and normally survive only when adhering to the ECM. Anoikis is the normal process of programmed cell death (apoptosis) occurring when anchorage-dependent cells become separated from the ECM. Cancer cells acquire the ability to resist anoikis, thus enhancing their ability to migrate, reattach, and establish themselves in secondary sites (72,73). Catecholamines were found to protect ovarian cancer cells from anoikis, both in vitro and in vivo. These effects were mediated by focal adhesion kinase (FAK), a tyrosine kinase that promotes cell adhesion, which demonstrated increased activation (phosphorylation of $pFAK^{Y397}$) in response to NE. Clinically, elevated levels of $pFAK^{Y397}$ were observed in the tumor tissue of patients with ovarian cancer reporting depression and those with higher levels of tumor NE. Furthermore, phosphorylated FAK was linked to poorer overall survival in these patients (74). These data demonstrate another pathway by which β-adrenergic signaling can promote metastatic progression of cancer.

BIOBEHAVIORAL FACTORS AND CANCER PROGRESSION

Stress Effects on Stromal Cells in the Tumor Microenvironment

Tumor growth is, to a large extent, shaped and promoted or inhibited by signaling between tumor cells and the cells of the microenvironment. In addition to the effects of stress hormones on tumor cells, there are marked effects on host cells such as macrophages in the tumor microenvironment. Monocytes are drawn to the tumor microenvironment by tumor-derived chemotactic factors and then differentiate into macrophages. However, under the influence of the proinflammatory microenvironment, macrophages are induced to shift from their phagocytic phenotype to a protumor phenotype that produces tumor-promoting factors such as VEGF and MMPs, while simultaneously downregulating the cellular immune response by production of immunosuppressive cytokines such as IL-10 and tumor growth factor β (75–78). TAMs are thus directly involved in promoting angiogenesis, tumor proliferation, invasion, metastases, and downregulation of adaptive immunity. TAM infiltration is also associated with poorer survival (79–81). Both NE and cortisol have been shown to increase production of MMP-9 from monocyte-derived macrophages (54). In a preclinical orthotopic model of mammary cancer, stress-induced neuroendocrine activation had minimal effects on the primary tumor but showed profound effects on metastatic spread of the tumor to distant sites. These effects were mediated by β-adrenergic effects on macrophages, which induced changes in tumor gene expression supporting metastasis along with macrophage differentiation to a tumor-supporting phenotype (M2). These effects were blocked by propranolol and by suppression of macrophage activities. These findings demonstrate stress effects on tumor metastatic spread via tumor-macrophage signaling (82). In patients with ovarian cancer, biobehavioral risk factors that have been associated with higher NE levels, such as depression and stress (83), have been related to increased TAM secretion of MMP-9 (54). Thus, stress-related effects on TAM may have important implications for tumor progression by promoting a microenvironment that favors tumor growth.

BIOBEHAVIORAL RISK FACTORS AND TUMOR GENE EXPRESSION

Biobehavioral profiles have been linked to modulation of gene expression in pathways related to tumor progression in ovarian cancer. Tumors from patients with ovarian cancer with high levels of depression and low levels of social support (high risk) were compared with those patients reporting low levels of depression and high levels of social support (low risk) and matched for histologic diagnosis, stage, grade, and age. Compared with their low-risk counterparts, tumors from high-risk patients showed more than 200 upregulated gene transcripts, many of which are involved in tumor progression pathways (e.g., cyclic adenosine monophosphate response element-binding, nuclear factor-κB, STAT, ELK1). Furthermore, high-risk patients demonstrated elevated levels of intratumoral, but not plasma, NE. These findings point to a distinctive gene expression fingerprint in primary ovarian tumors of patients with high levels of depression and low levels of social support, with β-adrenergic signal transduction as a likely mediator of these relationships (84).

GLUCOCORTICOID DYNAMICS AND CANCER PROGRESSION

The previous sections highlight the role of adrenergic pathways in tumor progression. However, glucocorticoids can directly mediate processes promoting tumor growth as well. Cortisol has been shown to stimulate growth of prostate cancer cells (85) and enhance proliferation of human mammary cancer cells by nearly two-fold (86). In addition, glucocorticoids have been shown to directly enhance a survival pathway in mammary cancer cells (87) and downregulate expression of DNA repair genes (88). Glucocorticoids are also known to activate survival genes in cancer cells, which could inhibit chemotherapy-induced apoptosis (89–91). These effects may be relevant in the context of pharmacological glucocorticoids that are given as a part of many chemotherapy regimens. In a murine breast cancer model, social isolation induced an elevated corticosterone stress response, greater tumor burden, and alterations in gene expression in metabolic pathways that are known to contribute to increased tumor growth (92). Glucocorticoids are also known to inhibit the cellular immune response and thus are thought to decrease immunosurveillance in the context of cancer (93–95). Thus, glucocorticoids have direct effects on tumor growth and development, resistance to chemotherapy, and effects on immunosurveillance.

BIOBEHAVIORAL FACTORS AND INFLAMMATION

Inflammatory processes are common in epithelial tumors, and inflammation serves as a tumor initiator and promoter (96,97). Both tumor cells and TAMs produce substantial levels of inflammatory cytokines, particularly IL-6 (97). Inflammatory cytokines are also produced after cancer treatments such as radiation. Such tumor- or treatment-derived proinflammatory cytokines can potentially activate CNS pathways, evoking a syndrome of "sickness behaviors" comprising behavioral and affective responses that mimic flu-like vegetative symptoms (98–100). Preclinical studies have now shown that presence of tumor in itself can induce elevations in peripheral and central proinflammatory cytokines, as well as vegetative depressive-like behaviors (101,102). In clinical samples, fatigued breast cancer survivors have been shown to have chronic elevations in peripheral inflammatory markers accompanied by lower levels of serum cortisol and flatter diurnal cortisol slopes (103–106). Fatigue and debility in patients with ovarian cancer have been associated with cortisol dysregulation, in particular, with elevated levels of nocturnal cortisol (106). These findings suggest a tumor-to-brain pathway, in which tumor- and treatment-derived proinflammatory cytokines may contribute to chronic inflammation, ultimately resulting in sickness behaviors. It is also quite possible that chronic inflammation elicits increased

cortisol production for inflammatory control, thereby contributing to HPA axis dysregulation (107–109).

CONCLUSIONS AND FUTURE DIRECTIONS

There is converging evidence from in vitro, in vivo, and clinical studies, reviewed in brief above, that biobehavioral and stress-related processes are linked with critical elements of the metastatic cascade in both animal and human models. Contributions of systemic factors such as stress hormones to the signaling between tumor and stromal cells seem to be a key factor in modulating downstream pathways, with important implications for progression. This burgeoning area of research is beginning to reveal a coherent picture of physiological pathways implicated in cancer progression that are sensitive to modulation by neuroendocrine and stress-related pathways.

However, there are many important questions that still need to be addressed. Much of the research described previously has focused on patients with ovarian or breast cancer and preclinical models of ovarian and mammary cancer. It will be important to determine whether similar processes are evidenced in other cancers, for example, in nonsolid tumors such as leukemia and lymphomas. In addition, further specification of the downstream effects of particular psychological constructs is needed at the tumor level. In the clinical literature, lack of perceived social support is a factor that emerges repeatedly in associations with biological variables related to cancer progression, and social isolation has shown similar effects in the preclinical literature. Understanding what it is about social relationships that underlie these associations will be important in future research.

Additional questions include the following: How much stress, in terms of thresholds or chronicity, is needed to modulate tumor-related pathways? Are there windows of treatment (e.g., after surgery, after completion of treatment, after recurrence) when effects of biobehavioral risk factors might be most important? What are interactions of biobehavioral factors with diet, toxins, and metabolic factors or factors related to sex, race, and ethnicity? Do biobehavioral risk factors promote conditions that favor cancer recurrence? To what extent do effects of biobehavioral factors on the tumor microenvironment influence disease progression and survival? The relationship between depression and FAK in light of the link between high level of FAK and poor ovarian cancer survival discussed previously is suggestive in this respect. However, further examination of the clinical implications of these biobehavioral-disease marker relationships will be important in future research.

These findings highlight the importance of translational research to identify pathways relevant for biobehavioral influences on cancer biology. Understanding the mechanisms by which biobehavioral signaling can modulate fatigue, pain, and cognitive symptoms and influence the effectiveness of conventional therapies is an important direction for future research. Pharmacological approaches including β-blockers, antidepressants, and anti-inflammatory agents are potentially reasonable candidates for testing in light of the findings discussed previously. Psychosocial, mind-body, and complementary interventions may also modulate stress-related pathways implicated in tumor progression. A better understanding of biobehavioral mechanisms involved in cancer progression may help the development of personalized therapy by helping to characterize patients most likely to benefit from innovative intervention strategies.

REFERENCES

1. Brock AJ. Greek Medicine: Being Extracts Illustrative of Medical Writers From Hippocrates to Galen. London, England: JM Dent and Sons; 1929.
2. Bleiker EMA, van der Ploeg HM, Hendriks JHCL, Adèr HJ. Personality factors and breast cancer development: a prospective longitudinal study. J Natl Cancer Inst 2008;88:1478–82.
3. Cassileth BR. Stress and the development of breast cancer: a persistent and popular link despite contrary evidence. Cancer 1996;77:1015–6.
4. Duijts SFA, Zeegers MPA, Borne BV. The association between stressful life events and breast cancer risk: a meta-analysis. Int J Cancer 2003; 107:1023–9.
5. Penninx BW, Guralnik JM, Pahor M, Ferrucci L, Cerhan JR, Wallace RB, Havlik RJ. Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst 1998;90:1888–93.
6. Lillberg K, Verkasalo PK, Kaprio J, Teppo L, Helenius H, Koskenvuo M. Stressful life events and risk of breast cancer in 10,808 women: a cohort study. Am J Epidemiol 2003;157:415–23.
7. Steel JL, Geller DA, Gamblin TC, Olek MC, Carr BI. Depression, immunity, and survival in patients with hepatobiliary carcinoma. J Clin Oncol 2007;25:2397–405.
8. Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 2009;115:5349–61.
9. Giese-Davis J, Collie K, Rancourt KMS, Neri E, Kraemer HC, Spiegel D. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol 2011;29:413–20.
10. Hamer M, Chida Y, Molloy GJ. Psychological distress and cancer mortality. J Psychosom Res 2009;66:255–8.
11. Palesh O, Butler LD, Koopman C, Giese-Davis J, Carlson R, Spiegel D. Stress history and breast cancer recurrence. J Psychosom Res 2007;63: 233–9.
12. Kroenke CH, Kubzansky LD, Schernhammer ES, Holmes MD, Kawachi I. Social networks, social support, and survival after breast cancer diagnosis. J Clin Oncol 2006;24:1105–11.
13. Sprehn GC, Chambers JE, Saykin AJ, Konski A, Johnstone PA. Decreased cancer survival in individuals separated at time of diagnosis: critical period for cancer pathophysiology? Cancer 2009;115:5108–16.
14. Kravdal O. The impact of marital status on cancer survival. Soc Sci Med 2001;52:357–68.
15. Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med 2010;40:1797–810.
16. Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol 2008;5:466–75.
17. Pinquart M, Duberstein PR. Associations of social networks with cancer mortality: a meta-analysis. Crit Rev Oncol Hematol 2010;75:122–37.
18. Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry 2003;54:269–82.
19. Petticrew M, Bell R, Hunter D. Influence of psychological coping on survival and recurrence in people with cancer: systematic review. BMJ 2002;325:1066–76.
20. Antoni M, Lutgendorf S, Cole S, Dhabhar FS, Sephton SE, McDonald PG, Stefanek M, Sood AK. The influence of biobehavioural factors on tumor biology: pathways and mechanisms. Nat Rev Cancer 2006;6: 240–8.
21. Levy S, Herberman R, Lee J, Whiteside T, Kirkwood J, McFeeley S. Estrogen receptor concentration and social factors as predictors of natural killer cell activity in early-stage breast cancer patients. Nat Immun Cell Growth Regul 1990;9:313–24.

BIOBEHAVIORAL FACTORS AND CANCER PROGRESSION

22. Levy S, Herberman R, Lippman M, D'Angelo T. Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer. J Clin Oncol 1987;5:348–53.

23. Levy S, Herberman R, Lippman M, D'Angelo T, Lee J. Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer. Behav Med 1991;17:67–75.

24. Levy S, Herberman R, Maluish A, Schlien B, Lippman M. Prognostic risk assessment in primary breast cancer by behavioral and immunological parameters. Health Psychol 1985;4:99–113.

25. Levy SM. Behavioral and immunological host factors in cancer risk. In: McCabe PM, Schneiderman N, Field TM, Skyler JS, editors. Stress, Coping and Disease. Hillsdale, NJ: Lawrence Erlbaum Associates; 1991:237–53.

26. Glaser R, Thorn B, Tarr K, Kiecolt-Glaser J, D'Ambrosio S. Effects of stress on methyltransferase synthesis: an important DNA repair enzyme. Health Psychol 1985;4:403–12.

27. Kiecolt-Glaser JK, Stephens RE, Lipetz PD, Speicher CE, Glaser R. Distress and DNA repair in human lymphocytes. J Behav Med 1985; 8:311.

28. Reiche EM, Nunes SO, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol 2004;5:617–25.

29. Zorrilla EP, Luborsky L, McKay JR. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001;15:199–226.

30. Irwin M. Psychoneuroimmunology of depression: clinical implications. Brain Behav Immun 2002;16:1–16.

31. Thornton LM, Andersen BL, Crespin TR, Carson WE. Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. Brain Behav Immun 2007;21:185–94.

32. Varker KA, Terrell CE, Welt M. Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobulin-like receptors. J Surg Res 2007;139:36–44.

33. Andersen B, Farrar WB, Golden-Kreutz D, Kutz LA, MacCallum R, Courtney ME, Glaser R. Stress and immune responses after surgical treatment for regional breast cancer. J Natl Cancer Inst 1998;90:30–6.

34. Blomberg BB, Alvarez JP, Diaz A, Romero MG, Lechner SC, Carver CS, Holley H, Antoni MH. Psychosocial adaptation and cellular immunity in breast cancer patients in the weeks after surgery: an exploratory study. J Psychosom Res 2009;67:369–76.

35. Sephton SE, Dhabhar FS, Keuroghlian AS, Giese-Davis J, McEwen BS, Ionan AC, Spiegel D. Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer. Brain Behav Immun 2009;23: 1148–55.

36. Von AD, Kang D, Carpenter J. Stress, optimism, and social support: impact on immune responses in breast cancer. Res Nurs Health 2007;30: 72–83.

37. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3:999–1005.

38. Garcia-Lora A, Algarra I, Garrido F. MHC Class I antigens, immune surveillance, and tumor escape. J Cell Physiol 2003;195:346–55.

39. Lutgendorf S, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, Sorosky JI, De Geest K, Ritchie J, Lubaroff DM. Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol 2005;23:7105–13.

40. Lutgendorf SK, Lamkin D, DeGeest K, Anderson B, Dao M, McGinn S, Zimmerman B, Maiseri H, Sood AK, Lubaroff DM. Depressed and anxious mood and T-cell cytokine producing populations in ovarian cancer patients. Brain Behav Immun 2008;22:890–900.

41. Andersen BA, Yang H-C, Farrar WB, Golden-Kreutz DM, Emery CF, Thornton LF, Young, DC, Carson WE. Psychologic intervention improves survival for breast cancer patients. Cancer 2008;113:3450–8.

42. Ben-Eliyahu S. The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology. Brain Behav Immun 2003;17:27–36.

43. Ben-Eliyahu S, Page GG, Yimira R, Shakhar G. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer 1999;80:880–8.

44. Glasner A, Avraham R, Rosenne E, Benish M, Zmora O, Shemer S, Meiboom H, Ben-Eliyahu S. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol 2010;184:2449–57.

45. Ben-Eliyahu S, Shakhar G, Page GG, Stefanski V, Shakhar K. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors. Neuroimmunomodulation 2000;8:154–64.

46. Benish M, Bartal I, Goldfarb Y, Levi B, Avraham R, Raz A, Ben-Eliyahu S. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 2008;15:2042–52.

47. Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 2003;10:972–92.

48. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453–8.

49. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4–6.

50. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:442–7.

51. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983–5.

52. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008;5:194–204.

53. Lutgendorf SK, Johnsen EL, Cooper B, Anderson B, Sorosky JI, Buller RE, Sood AK. Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer 2002;95:808–15.

54. Lutgendorf SK, Lamkin DM, Jennings NB, Arevalo JM, Penedo F, DeGeest K, Langley RR, Lucci JA 3rd, Cole SW, Lubaroff DM, Sood AK. Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin Cancer Res 2008;14:6839–46.

55. Nausheen B, Carr NJ, Peveler RC, Moss-Morris R, Verrill C, Robbins E, Nugent KP, Baker AM, Judd M, Gidron Y. Relationship between loneliness and proangiogenic cytokines in newly diagnosed tumors of colon and rectum. Psychosom Med 2010;72:912–6.

56. Sharma A, Greenman J, Sharp DM, Walker LG, Monson JR. Vascular endothelial growth factor and psychosocial factors in colorectal cancer. Psychooncology 2008;17:66–73.

57. Lutgendorf SK, Cole S, Costanzo E, Bradley S, Coffin J, Jabbari S, Rainwater K, Ritchie JM, Yang M, Sood AK. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 2003;9:4514–21.

58. Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, Jewell S, Flavahan NA, Morrison C, Yeh PE, Lemeshow S, Glaser R. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase MMP-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006;66:10357–64.

59. Yang EV, Kim SJ, Donovan EL, Chen M, Gross AC, Webster Marketon JI, Barsky SH, Glaser R. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 2009;23: 267–75.

60. Yang EV, Donovan EL, Benson DM, Glaser R. VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine. Brain Behav Immun 2008;22:318–23.

61. Thaker P, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Chronic stress promotes tumor growth and metastasis in ovarian carcinoma. Nat Med 2006;12:939–44.

62. Lee J, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res 2009;15: 2695–702.

63. Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Jennings N, Arevalo J, Lutgendorf SK, Gallick GE, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK. Stress hormones regulate IL-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem 2007;282:29919–26.

64. Cohen T, Nahari D, Cerem LW, Neufield G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996;271:736–41.

65. Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J,

Lubaroff DM. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer 2005;104:305–13.

66. Lutgendorf SK, DeGeest K, Dahmoush L, Farley D, Penedo F, Bender D, Goodheart M, Buekers TE, Mendez L, Krueger G, Clevenger L, Lubaroff DM, Sood AK, Cole SW. Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain Behav Immun 2011;25:250–5.

67. Hagemann T, Robinson SC, Schulz M, Trümper L, Balkwill FR, Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 2004;25:1543–9.

68. Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SW. Stress hormone mediated invasion of ovarian cancer cells. Clin Cancer Res 2006;12:369–75.

69. Masur K, Niggemann B, Zanker KS, Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 2001;61:2866–9.

70. Drell TL, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 2003;80:63–70.

71. Yang E, Bane CM, MacCallum RC, Kiecolt-Glaser JK, Malarkey WB, Glaser R. Stress-related modulation of matrix metalloproteinase expression. J Neuroimmunol 2002;133:144–50.

72. Shanmugathasan M, Jothy S. Apoptosis, anoikis and their relevance to the pathobiology of colon cancer. Pathol Int 2000;50:273–9.

73. Yawata A, Adachi M, Okuda H, Naishiro Y, Takamura T, Hareyama M, Takayama S, Reed JC, Imai K. Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells. Oncogene 1998;16:2681–6.

74. Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 2010;120:1515–23.

75. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71–8.

76. Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 2008;267:204–15.

77. Sica A, Rubino L, Mancino A, Larghi P, Porta C, Rimoldi M, Solinas G, Locati M, Allavena P, Mantovani A. Targeting tumour-associated macrophages. Expert Opin Ther Targets 2007;11:1219–29.

78. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour. Eur J Cancer 2006;42:717–27.

79. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196:254–65.

80. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211–7.

81. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 2005;14:425–31.

82. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L, Sood AK, Cole SW. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 2010;70:7042–52.

83. Hughes JW, Watkins L, Blumenthal JA, Kuhn C, Sherwood A. Depression and anxiety symptoms are related to increased 24-hour urinary norepinephrine excretion among healthy middle-aged women. J Psychosom Res 2004;57:353–8.

84. Lutgendorf SK, DeGeest K, Sung CY, Arevalo JMG, Penedo F, Lucci JA III, Goodheart M, Lubaroff D, Farley D, Sood AK, Cole SW. Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun 2009;23:176–83.

85. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000;6:703–6.

86. Simon WE, Albrecht M, Trams G, Dietel M, Holzel F. In vitro growth

87. Moran TJ, Gray S, Mikosz CA, Conzen SD. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res 2000;60:867–72.

88. Antonova L, Mueller CR. Hydrocortisone down-regulates the tumor suppressor gene BRCA1 in mammary cells: a possible molecular link between stress and breast cancer. Genes Chromosomes Cancer 2008;47:341–52.

89. Herr I, Ucur E, Herzer KEA. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res 2003;63:3112–20.

90. Wu W, Chaudhuri S, Brickley DR. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004;64:1757–64.

91. Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD. Dexamethasone decreases xenograft response to paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther 2006;5:933–40.

92. Williams JB, Pang D, Delgado B, Kocherginsky M, Tretiakova M, Krausz T, Pan D, He J, McClintock MK, Conzen SD. A model of gene-environment interaction reveals altered mammary gland gene expression and increased tumor growth following social isolation. Cancer Prev Res (Phila) 2009;2:850–61.

93. Elenkov IJ. Glucocorticoids and the T_H1/T_H2 balance. Ann N Y Acad Sci 2004;1024:138–46.

94. Holbrook N, Cox W, Horner H. Direct suppression of natural killer activity in human peripheral blood leukocyte cultures by glucocorticoids and its modulation by interferon. Cancer Res 1983;43:4019–25.

95. Zhou J, Olsen S, Moldovan J, Fu X, Sarkar FH, Moudgil VK, Callewaert DM. Glucocorticoid regulation of natural cytotoxicity: effects of cortisol on the phenotype and function of a cloned human natural killer cell line. Cell Immunol 1997;178:108–16.

96. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539–45.

97. Hagemann T, Balkwill F, Lawrence T. Inflammation and cancer: a double-edged sword. Cancer Cell 2007;12:300–1.

98. Maier S, Watkins L. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 1998;105:83–107.

99. Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun 2003;17:S119–24.

100. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006;27:24–31.

101. Pyter LM, Pineros V, Galang JA, McClintock MK, Prendergast BJ. Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic-pituitary-adrenal axis regulation. Proc Natl Acad Sci U S A 2009;106:9069–74.

102. Lamkin DM, Lutgendorf SK, Lubaroff DM, Sood AK, Beltz TG, Johnson AK. Cancer induces inflammation and depressive-like behavior in the mouse: modulation by social housing. Brain Behav Immun 2011;25:555–64.

103. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002;64:604–11.

104. Collado-Hidalgo A, Bower ME, Ganz PA, Cole SW, Irwin MR. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 2006;12:2759–66.

105. Bower JE, Ganz PA, Dickerson SS, Petersen L, Aziz N, Fahey JL. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 2005;30:92–100.

106. Weinrib A, Sephton SE, DeGeest K, Penedo F, Bender D, Zimmerman B, Kirschbaum C, Sood AK, Lubaroff DM, Lutgendorf SK. Diurnal cortisol dysregulation: links with depression and functional disability in women with ovarian cancer. Cancer 2010;116:4410–9.

107. Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, DeGeest K, Costanzo ES, Henderson PJ, Sephton SE, Rohleder N, Lucci JA 3rd, Cole S, Sood AK, Lubaroff DM. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 2008;26:4820–7.

108. Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S, Pearce BD, Landry J, Glover S, McDaniel JS, Nemeroff CB. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001;158:1252–7.

109. Jehn CF, Kuehnhardt D, Bartholomae A, Pfeiffer S, Krebs M, Regierer AC, Schmid P, Possinger K, Flath BC. Biomarkers of depression in cancer patients. Cancer 2006;107:2723–9.